Contract Research Organization Medpace Lifts FY22 Guidance, Highlights FY23 Outlook

  • Medpace Holdings Inc's MEDP Q3 revenue increased 29.8% Y/Y to $383.7 million, beating the consensus of $357.18 million, representing a backlog conversion rate of 17.7%.
  • On a constant currency organic basis, Q3 revenue was up 31.9%.
  • As of September 30, 2022, Backlog grew 20.9% to $2.2 billion. Net new business awards were $470.9 million, representing a net book-to-bill ratio of 1.23x.
  • Q3 EBITDA increased 48.5% to $89.3 million, or 23.3% of revenue, compared to $60.1 million, or 20.3% of revenue, a year ago.
  • Medpace posted an EPS of $2.05, up from $1.29 a year ago and beating the consensus of $1.47.
  • Financial Guidance: Medpace raised FY22 sales guidance to $1.44-$1.46 billion, versus the prior guidance of $1.405-$1.435 billion and the consensus of $1.41 billion.
  • EBITDA is expected to be $302-$310 million, versus the previous guidance of $268-$280 million 
  • Medpace expects EPS of $6.88-$7.00 compared to prior guidance of $6.07-$6.36 and the consensus of $6.15.
  • For FY23, the company forecasts sales of $1.68-$1.74 billion, with EBITDA of $325-$350 million.
  • Price Action: MEDP shares traded higher by 28.13% at $203.26 in premarket on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!